Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate
- 15 September 1984
- Vol. 54 (S1) , 1208-1215
- https://doi.org/10.1002/1097-0142(19840915)54:1+<1208::aid-cncr2820541319>3.0.co;2-k
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Hochdosiertes Medroxyprogesteronacetat beim metastasierenden Mammakarzinom: Beziehung zwischen Krankheitsverlauf und HormonprofilenJournal of Molecular Medicine, 1983
- Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncologyCancer Chemotherapy and Pharmacology, 1982
- The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancerCancer Chemotherapy and Pharmacology, 1982
- On the mechanism of action of progestinsActa Endocrinologica, 1981
- Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routesCancer Chemotherapy and Pharmacology, 1980
- Estradiol and progesterone receptors in normal and neoplastic endometrium: Correlations between receptors, histopathological examinations and clinical responses under progestin therapyInternational Journal of Cancer, 1979
- The Effect of Medroxyprogesterone Acetate on the Pituitary-Adrenal AxisJournal of Clinical Endocrinology & Metabolism, 1976
- GLC Determination of Medroxyprogesterone Acetate in PlasmaJournal of Pharmaceutical Sciences, 1974
- Source of Estrogen Production in Postmenopausal Women1Journal of Clinical Endocrinology & Metabolism, 1973
- Progestins in the Medical Management of Active Acromegaly1Journal of Clinical Endocrinology & Metabolism, 1970